Table 2.

Antiviral and cytotoxicity effects of two- to three-drug combination therapy in HCV-replicon-containing Huh-7 cells (Clone B)

Treatment	Ratio	EC50 μM	EC90 μM	CC50, μM*
2′-C-MeC + IFN-α2b	1:3	0.1	1.3	>33
2′-C-MeC + IFN-α2b	1:2	0.4	1.8	>33
2′-C-MeC + IFN-α2b	1:1	0.3	1.6	>33
2′-C-MeC + IFN-α2b	2:1	0.02	0.8	>33
2′-C-MeC + IFN-α2b + RBV	2:1:1	0.1	4.9	>11
2′-C-MeC + IFN-α2b + RBV	1:1:1	0.2	2.2	>3.6
2′-F-C-MeC + IFN-α2b	1:10	0.09	0.6	>33
2′-F-C-MeC + IFN-α2b	1:5	0.1	0.8	>33
2′-F-C-MeC + IFN-α2b	1:1.5	0.2	1.2	>33
2′-F-C-MeC + IFN-α2b	1:1	0.02	0.4	>33
2′-F-C-MeC + IFN-α2b + RBV	2:1:1	0.2	2.2	>11
2′-F-C-MeC + IFN-α2b + RBV	1:1:1	0.09	1.2	>11
2′-F-C-MeC + IFN-α2b + RBV	1:1.5:1.5	0.2	2.6	>3.6

Values represent the apparent potency of the first compound (2′-C-MeC or 2′-F-C-MeC) listed in the combination.

^*Cytotoxicity concentration (CC₅₀) represents only the first compound listed in the combination, and it was tested by calculating the Δ threshold cycle of rRNA values. EC₅₀, 50% effective concentration; EC₉₀ 90% effective concentration; IFN, interferon; RBV, ribavirin.